M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status:
Active, not recruiting
Trial end date:
2023-05-09
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate safety and efficacy in participants treated
with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT
plus placebo followed by durvalumab.